Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
  • Policy / Pricing

AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies

BioSpace

Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs.

Policy / PricingImmunology & InflammationRead full story

pharminent April 7, 2026 (Last updated: April 7, 2026)

BioSpace

Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie’s deal with the White House to avoid tariffs.

Policy / PricingImmunology & InflammationRead full story

Post navigation

Previous: Kennedy changes vaccine panel charter after legal setback
Next: Gilead strikes again, penning $5bn deal to buy Tubulis

Related Stories

  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Policy / Pricing

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain

pharminent August 13, 2026
  • Policy / Pricing

Trump signs order that nearly halves childhood immunisation coverage

pharminent August 11, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.